Conference Coverage

Children with Down syndrome and ALL have good outcomes today


 

REPORTING FROM ASPHO 2018


There were no significant differences between patients with or without Down syndrome in the proportion of either rapid or slow early responses. Significantly fewer patients with Down syndrome had standard-risk low disease, and significantly more had average or high-risk disease.

Patients with Down syndrome initially had 11.5% excess risk for death during induction, but following additional treatment modifications, the excess risk decreased to 1.7%.

Among patients with Down syndrome, one died during intensive consolidation, and two died during delayed intensification. All three deaths were due to infections. No patients with Down syndrome died during maintenance.

Patients with Down syndrome also had a significantly increased risk for infection during induction (P less than .0001).

Pages

Recommended Reading

Blinatumomab triggers complete MRD response in ALL
MDedge Hematology and Oncology
Relapse rate drives stem cell transplant failure in pediatric ALL patients
MDedge Hematology and Oncology
Cooperation can drive T-ALL, study shows
MDedge Hematology and Oncology
Drug receives orphan designation for ALL
MDedge Hematology and Oncology
Art education benefits blood cancer patients
MDedge Hematology and Oncology
Team uses iPSCs to create ‘universal’ CAR T cells
MDedge Hematology and Oncology
Study reveals gene variants that predispose kids to ALL
MDedge Hematology and Oncology
Gene variants linked to survival after HSCT
MDedge Hematology and Oncology
Health Canada approves product for adult ALL
MDedge Hematology and Oncology
Team maps genetic evolution of T-ALL subtype
MDedge Hematology and Oncology